Table 3.
Regional Mean i‐TTR by Prior VKA Experience
| N | i‐TTR, mean % | SE | Median (25th, 75th) | Parameter Estimate | P Value | |
|---|---|---|---|---|---|---|
| VKA naïve | ||||||
| East Asia | 356 | 47.3 | 1.1 | 49 (34, 63) | −7.75 | 0.0005 |
| India | 87 | 32.6 | 2.5 | 29 (13, 49) | −22.46 | <0.0001 |
| Eastern Europe | 1414 | 45.2 | 0.6 | 47 (31, 61) | −9.90 | <0.0001 |
| Western Europe/similar | 233 | 57.8 | 1.3 | 62 (48, 72) | 2.72 | 0.25 |
| South Africa | 29 | 46.5 | 4.8 | 47 (26, 64) | −8.57 | 0.054 |
| Latin America | 348 | 50.1 | 1.1 | 54 (37, 64) | −5.00 | 0.025 |
| Canada/United States | 129 | 55.1 | 1.8 | 58 (46, 70) | Ref | |
| VKA experienced but warfarin naïve* | ||||||
| East Asia | 0 | |||||
| India | 20 | 45.5 | 5.1 | 47 (28, 63) | −14.72 | 0.0006 |
| Eastern Europe | 619 | 53.6 | 0.8 | 55 (43, 68) | −6.53 | <0.0001 |
| Western Europe/similar | 399 | 60.1 | 0.9 | 63 (50, 73) | Ref | |
| South Africa | 0 | |||||
| Latin America | 293 | 60.1 | 1.0 | 62 (50, 72) | −0.08 | 0.96 |
| Canada/United States | 3 | 64.1 | 3.8 | 65 (57, 70) | ||
| Warfarin experienced | ||||||
| East Asia | 371 | 53.3 | 1.1 | 56 (41, 68) | −11.83 | <0.0001 |
| India | 23 | 39.9 | 4.6 | 42 (27, 52) | −25.25 | <0.0001 |
| Eastern Europe | 630 | 55.9 | 0.7 | 58 (45, 70) | −9.16 | <0.0001 |
| Western Europe/similar | 456 | 68.7 | 0.7 | 70 (60, 79) | 3.61 | 0.64 |
| South Africa | 95 | 57.3 | 2.1 | 63 (46, 71) | −7.76 | <0.0001 |
| Latin America | 283 | 56.4 | 1.2 | 59 (45, 71) | −8.75 | <0.0001 |
| Canada/United States | 1195 | 65.1 | 0.5 | 67 (55, 78) | Ref | |
i‐TTR indicates individual patient‐level time in therapeutic range; VKA, vitamin K antagonist.
*
Because there are only 3 patients in this group in North America, Western Europe is used as the reference instead. There are no patients in this group in East Asia or South Africa.